Tumor-associated mitochondrial antigen (TAMA)

Tumor-associated mitochondrial antigens (TAMAs) are a class of immunogenic proteins and peptides derived from the mitochondria of malignant cells, primarily arising from somatic mutations in mitochondrial DNA (mtDNA) or the aberrant overexpression of mitochondrial proteins. These antigens function as neoantigens that are processed and presented on the cell surface via MHC class I molecules, where they can be recognized by the host's adaptive immune system, particularly CD8+ T cells. In cancer therapy, TAMAs have emerged as promising targets for personalized vaccines and immunotherapies, as mtDNA mutations are highly prevalent and often tumor-specific across various malignancies, including renal cell carcinoma and melanoma. Vaccination with TAMAs has been shown to elicit robust anti-tumor immune responses, increase the infiltration of cytotoxic T lymphocytes into the tumor microenvironment, and promote vascular normalization through interferon-gamma (IFN-γ) signaling. Furthermore, the induction of immunogenic cell death (ICD) by agents like IR-780 can enhance the exposure of these antigens, potentially synergizing with immune checkpoint inhibitors to overcome therapeutic resistance. This dual action of direct tumor cell killing and immune-mediated vascular remodeling makes TAMAs a unique and potent target class in the evolving landscape of precision oncology.

Other names

Tumor-associated mitochondrial antigensMitochondrial neoantigenMitochondrial-derived tumor antigenmtDNA-encoded neoantigen

Vaccination with TAMAs or induction of their exposure (e.g., via IR-780) triggers the presentation of mitochondrial neoantigens on MHC class I molecules, leading to the activation and recruitment of antigen-specific CD8+ T cells. This immune response promotes tumor cell lysis and induces vascular remodeling through IFN-gamma-dependent mechanisms, which can sensitize tumors to immune checkpoint inhibition.